Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Teleflex Incorporated (TFX)

NYSE: TFX · Surgical & Medical Instruments & Apparatus · Wayne, PA

Our rating: Cautious

Cautious reaffirmed at $150.87, moderate conviction, November 6, 2026.

Breaks if: The cautious view is wrong if Teleflex reports a free cash flow margin above 12% in each of the next two consecutive quarterly filings — confirming the net loss was dominated by non-cash charges and the underlying business is a solid cash generator. A stock price that holds above $195 for the balance of the next twelve months would similarly indicate the market has found evidence of durable value creation not visible in the current reported figures.

Key figures

Market value$6.4B
Revenue, last 12 months$2.3B
Net income, last 12 months$305M
Free cash flow, last 12 monthsn/a
Price to earnings21.0×
Free cash flow yieldn/a
Dividend yield0.8%
Operating margin9.4%
Return on equity8.3%
Beta to the S&P 5000.63
Volatility, annualized37.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$568M0.1%$22.28n/a
June 30, 2026$570M28.9%$2.28n/a
March 31, 2026$548M32.3%$-0.18n/a
December 31, 2025$569M28.7%$-16.15n/a
September 28, 2025$567M33.0%$-9.24n/a
June 29, 2025$443M5.7%$2.77n/a
March 30, 2025$414M0.3%$2.07n/a
December 31, 2024$442M−190.6%$-2.93n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

8 ledger entries and 54 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.